<!DOCTYPE html>
<html>
  <head>
    <meta charset="utf-8"/>
    <meta property="og:url" content="https://www.thecerbatgem.com/2019/11/25/geron-co-nasdaqgern-receives-3-80-consensus-target-price-from-analysts.html"/>
    <meta property="og:site_name" content="The Cerbat Gem"/>
    <meta property="article:published_time" content="2019-11-25T07:49:14+00:00"/>
    <meta property="og:title" content="Geron Co. (NASDAQ:GERN) Receives $3.80 Consensus Target Price from Analysts"/>
    <meta property="og:description" content="Geron Co. (NASDAQ:GERN) has earned an average recommendation of “Buy” from the eight analysts that are presently covering the firm, MarketBeat reports. One investment analyst has rated the stock with a sell recommendation, two have issued a hold recommendation and five have assigned a buy recommendation to the company. The average 1-year target price among […]"/>
  </head>
  <body>
    <article>
      <h1>Geron Co. (NASDAQ:GERN) Receives $3.80 Consensus Target Price from Analysts</h1>
      <address><time datetime="2019-11-25T07:49:14+00:00">25 Nov 2019, 07:49</time> by <a rel="author" href="https://www.thecerbatgem.com/author/scott" target="_blank">Scott Moore</a></address>
      <figure>
        <img src="https://www.americanbankingnews.com/wp-content/timthumb/timthumb.php?w=250&amp;zc=1&amp;src=https://www.marketbeat.com/logos/geron-co-logo.jpg"/>
      </figure>
      <p>Geron Co. (NASDAQ:GERN) has earned an average recommendation of “Buy” from the eight analysts that are presently covering the firm, <a href="https://www.marketbeat.com/">MarketBeat</a> reports. One investment analyst has rated the stock with a sell recommendation, two have issued a hold recommendation and five have assigned a buy recommendation to the company. The average 1-year target price among analysts that have updated their coverage on the stock in the last year is $3.80.</p>
      <p>A number of equities research analysts have commented on GERN shares. HC Wainwright started coverage on shares of Geron in a research note on Tuesday, September 3rd. They set a “buy” rating and a $4.00 target price on the stock. B. Riley started coverage on shares of Geron in a research note on Tuesday, November 19th. They set a “buy” rating and a $4.00 target price on the stock. Cantor Fitzgerald started coverage on shares of Geron in a research note on Thursday, August 15th. They set an “overweight” rating and a $4.00 target price on the stock. Needham &amp; Company LLC restated a “buy” rating and set a $3.00 target price on shares of Geron in a research note on Thursday, November 7th. Finally, BidaskClub cut shares of Geron from a “sell” rating to a “strong sell” rating in a research note on Tuesday, November 19th.</p>
      <p>A number of institutional investors and hedge funds have recently made changes to their positions in the business. Summit X LLC grew its holdings in Geron by 20.1% during the 3rd quarter. Summit X LLC now owns 92,607 shares of the biopharmaceutical company’s stock valued at $125,000 after buying an additional 15,500 shares in the last quarter. DekaBank Deutsche Girozentrale grew its holdings in shares of Geron by 64.0% in the second quarter. DekaBank Deutsche Girozentrale now owns 41,000 shares of the biopharmaceutical company’s stock valued at $62,000 after purchasing an additional 16,000 shares in the last quarter. Rudd International Inc. purchased a new position in shares of Geron in the second quarter valued at $30,000. Rhumbline Advisers grew its holdings in shares of Geron by 9.5% in the third quarter. Rhumbline Advisers now owns 274,615 shares of the biopharmaceutical company’s stock valued at $365,000 after purchasing an additional 23,882 shares in the last quarter. Finally, Tower Research Capital LLC TRC grew its holdings in shares of Geron by 482.4% in the second quarter. Tower Research Capital LLC TRC now owns 29,801 shares of the biopharmaceutical company’s stock valued at $42,000 after purchasing an additional 24,684 shares in the last quarter. 29.16% of the stock is owned by institutional investors and hedge funds.</p>
      <p><a href="https://www.marketbeat.com/stocks/NASDAQ/GERN/price-target/">NASDAQ GERN</a> opened at $1.30 on Friday. Geron has a 12 month low of $0.95 and a 12 month high of $2.14. The stock has a market cap of $267.70 million, a price-to-earnings ratio of -8.13 and a beta of 2.50. The company’s 50 day moving average is $1.44 and its two-hundred day moving average is $1.42.</p>
      <p>Geron (NASDAQ:GERN) last released its earnings results on Wednesday, November 6th. The biopharmaceutical company reported ($0.08) EPS for the quarter, topping analysts’ consensus estimates of ($0.14) by $0.06. Geron had a negative net margin of 7,044.88% and a negative return on equity of 29.22%. The company had revenue of $0.13 million for the quarter, compared to analysts’ expectations of $0.10 million. During the same quarter last year, the business earned $0.24 EPS. Sell-side analysts predict that Geron will post -0.42 earnings per share for the current fiscal year.</p>
      <p>
        <b>About Geron</b>
      </p>
      <p>Geron Corporation, a clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for hematologic myeloid malignancies. The company supports the clinical stage development of imetelstat, a telomerase inhibitor for the treatment of hematologic myeloid malignancies.</p>
      <p>Featured Story: <a href="https://www.marketbeat.com/financial-terms/calculate-return-on-equity/">Return on Equity (ROE)</a></p>
      <figure>
        <img src="https://www.marketbeat.com/scripts/RatingsChart.ashx?Prefix=NASDAQ&amp;Symbol=GERN"/>
      </figure>
    </article>
  </body>
</html>